CA2162045A1 - Electrochemical sensors - Google Patents
Electrochemical sensorsInfo
- Publication number
- CA2162045A1 CA2162045A1 CA002162045A CA2162045A CA2162045A1 CA 2162045 A1 CA2162045 A1 CA 2162045A1 CA 002162045 A CA002162045 A CA 002162045A CA 2162045 A CA2162045 A CA 2162045A CA 2162045 A1 CA2162045 A1 CA 2162045A1
- Authority
- CA
- Canada
- Prior art keywords
- membrane
- erythrocyte
- test strip
- aggregating agent
- porous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012528 membrane Substances 0.000 claims abstract description 180
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 61
- 238000012360 testing method Methods 0.000 claims abstract description 40
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 29
- 239000011148 porous material Substances 0.000 claims abstract description 29
- 230000004931 aggregating effect Effects 0.000 claims abstract description 28
- 230000007717 exclusion Effects 0.000 claims abstract description 15
- 229920001600 hydrophobic polymer Polymers 0.000 claims abstract description 13
- 239000011159 matrix material Substances 0.000 claims abstract description 12
- 238000011065 in-situ storage Methods 0.000 claims abstract description 4
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 30
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 29
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 29
- 229920002307 Dextran Polymers 0.000 claims description 26
- 210000004369 blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 19
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 238000005507 spraying Methods 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 102000007327 Protamines Human genes 0.000 claims description 2
- 108010007568 Protamines Proteins 0.000 claims description 2
- 238000002848 electrochemical method Methods 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229940048914 protamine Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000010410 layer Substances 0.000 claims 6
- 239000002356 single layer Substances 0.000 claims 1
- 238000009718 spray deposition Methods 0.000 abstract description 5
- 229920000642 polymer Polymers 0.000 description 49
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 47
- 239000000243 solution Substances 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 210000002381 plasma Anatomy 0.000 description 25
- 235000012000 cholesterol Nutrition 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 239000004677 Nylon Substances 0.000 description 13
- 229920001778 nylon Polymers 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- 239000007921 spray Substances 0.000 description 12
- 230000032258 transport Effects 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 238000007639 printing Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- 238000003618 dip coating Methods 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 5
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000007650 screen-printing Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- -1 Poly(vinyl butyral) Polymers 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 241000282346 Meles meles Species 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 206010039238 Rouleaux formation Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000007761 roller coating Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/06—Flat membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/14—Dynamic membranes
- B01D69/141—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/002—Electrode membranes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3272—Test elements therefor, i.e. disposable laminated substrates with electrodes, reagent and channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5002—Partitioning blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/40—Semi-permeable membranes or partitions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/817—Enzyme or microbe electrode
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/969—Multiple layering of reactants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/97—Test strip or test slide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Abstract
Erythrocyte exclusion membranes suited for test strips of electrochemical sensors have a porous matrix and a mobile erythrocyte aggregating agent. The membranes typically comprise a water-insoluble hydrophobic polymer incorporating a hydrophobic polymer and with the erythrocyte aggregating agent. Such membranes can have a pore size which is several times layer than the diameter of erythrocytes, and allow rapid passage of plasma by holding back the erythrocytes as rouleaux at the surface of the membrane. The membranes are preferably made by forming in situ on a test strip using spray casting.
Description
2~62~4~
ELECTROCHEMICAL SENSORS
Introduction The present invention relates to electrochemical sensors, and more particularly but not exclusively to electrochemical biosensors. The present invention further relates to a method of manufacture of test strips for use in such sensors.
Background of the Inventio~
There is an increasing public awareness of the diagnostic significance of levels of components in the blood and other body fluids, and many sensors are designed for non-expert use. A particular goal is the provision of electrochemical sensors which do not require elaborate preparation of a test sample, and can rapidly give a result merely by application of the body fluid to a test strip. Good sensitivity is achieved usually with a biochemically specific reaction, such as by enzymatic catalysis of a reaction of the component to be detected. The reaction results in transfer of charge which can be q~l~lit~tively or 4~ ely detected, for instance by an amperometric procedure.
Amperometric biosensors for p~"rwlll~.lg diagnostic tests for components of body fluids are described, for exarnple, in US Patent 4545382, European Patent 127958 and European Patent 351891. Such devices offer the facility for rapid, convenient and specific measurements of analyte components in blood by lay users, and a sensor for glucose is commercially available as the MediSense ~ ExacTech g) sensor.
.
Whole blood is a complex, predomin~tely aqueous mixture cont~inin~
dissolved gases, simple dissociated and hydrated ions, materials in colloidal or other form of solution, small scale cellular debris, and living cellular components including red blood cells, the erythrocytes. It is WO 94/27140 21 ~ 2 Q~ 5 2 PCT/GB94/01011 sometimes difficult to achieve reproducible analytical results with electrochemical sensors when using whole blood samples. Varia~ions in red cell concentration, the h~em~tocrit, is the main contributor to inaccuracies in using whole blood samples for electrochemical sensors.
Accordingly, there is a need to develop improved electrochemical sensors which are less dependent on the h~em~tocnt of the blood. To this end, there have been proposals for overlay membranes which serve to exclude erv~rocytes so that the sensor itself is only contacted by blood plasma.
Illustrative examples of proposals for erythrocyte exclusion membranes are to be found in published EP-A 289269 and other patent literature.
There are difficulties in developing a s~ti~f~etory ery~rocyte exclusion membrane suited for test strips such as amperometric electrode test strips.
A hurn~n erythrocyte is deformable in vivo to pass through lllmin~l di~meters as small as 2 or 3 ,um, and thus membranes of this porosity are ineffective, either because the erythrocytes leak through by deformation or bec~llee the erythrocytes plug the pores to prevent passage of the plasma.
Where the porosity is further re~llce~l, the transport of plasma is difficult.
In this respect, the typical volume of the blood sample for an amperometric glucose test is only 20 ~1 and yet gravity has to provide the principal driving force, with capillary forces providing only a secondary driving force. Given the goal of m~ or redueing me~ellrement times, where the period for a complete glucose test is typically 30 seconde, rapid transport of the plasma through the membrane is needed.
Thus, the transport of the plasma requires an open membrane structure, while the sep~dlion of erythrocytes ~ n~le a closed membrane structure. In t~e light of these contradictory requirements, it becomes clear that conventional membrane systems are not entirely suitable.
US Patent 5,055,195 describes the use of retention substrates which bring about strong co~ hon of blood so that the corpuscular components are effectively retained in a paper or glass fibre fleece and are sepalated from the plasma. This object is achieved by using retention substrates which contain two strongly polar groups which are connected by a non-polar bridge. The retentio~ substrates are preponderantly dyestuffs, and they bring about random clurnping.
2~
Objects of the Invention An object of the present invention is provide an improved erythrocyte exclusion membrane for an electrochemical sensor. In this respect, it is an object to provide an improved porous erythrocyte exclusion membrane which permits rapid transport of plasma through the membrane, while subst~nti~lly excluding the passage of erythrocytes. A particular object is the provision of a disposable single-use electrode test strip for an amperometric biosensor, for use with a sample of whole blood, which is less dependent on the haematocrit of the blood.
A related object is to provide a new method for the m~nllf~cture of test strips.
S~lmm~ry of the Invention According to the present invention, there is provided an erythrocyte exclusion membrane comprising a porous matrix including an erythrocyte aggregating agent.
The erythrocyte aggregating agent is an agent which can induce the formation of erythrocyte aggregates known as rouleaux. Such rouleaux have a diameter of typically 50 to 100 times that of an individual e~throcyte, and are not r~n~lom clumps. Accordingly, with the inclusion of the erythrocyte aggregating agent, the porosity of the membrane can be such that individual erythrocytes might otherwise pass through the matrix, but rouleaux can not pass through the matrix. The ery~rocyte aggregating agent is present at or migrates to the surface of the membrane to bring about formation of the rouleaux. In this way, the erythrocytes are held outside the membrane pores, allowing effective transport of the plasma with separation ~om the erythrocytes.
Thus, the present invention provides a test strip for an electrochemical sensor for contact with whole blood in order to effect an electrochemical measurement. The test strip has an exclusion layer in the form of a porous membrane with an erythrocyte aggregating agent. The membrane excludes red blood cells from contact with the sensing electrodes by WO 94/27140 ~ 2 ~ 4 4 PCT/GB94/01011 aggregating them at the surface of the membrane and excluding them as e~hrocyte rouleaux. By virtue of the presence of the exclusion laver, the sensing electrodes are exposed only to plasma, so that the red blood cells can not i~llelfere. In this way, reproducible results are more easily achieved, even for disposable test strips made in high volume and at low cost.
Preferred Embodiments The l,refelled porous matrix ofthe polymeric membrane mainly consists of a water-insoluble hydrophobic polymer so that this matrix will not be si~nificantly altered by the water present in whole blood. However, membranes con~i~ting of such material have poor wethng ability. In order to obtain effective plasma transport through the membrane pores, the porous hydrophobic matnx ~fe,ably incorporates a hydrophilic polymer.
A ,~)rer~lled membrane thus comprises at least three groups of polymeric materials, namely a hydrophobic polymer, a hydrophilic polymer, and a mobile erythrocyte aggregating agent.
The hydrophobic polymer is a water-insoluble but organic solvent-soluble membrane-forming polymer which provides the desired porous membrane structure. Such polymers are well known and typically contain hydrophobic functional groups at a ~lomin~nt level, though a rninor proportion of hydrophilic fimctional groups can be present. F.~mples of the hydrophobic polymer include cellulose acetate propionate, cellulose acetate, polyvinyl butyral, polystyrene, etc.
The hydrophilic polymer is a water-soluble and organic solvent-soluble polvmer which provides good membrane permeability to plasma and especially dissolved analytes in the plasma. Such polymers are well known and typically contain hydrophilic fi~nctional groups at a dominant level, though a minor proportion of hydrophobic functional groups can be present. Examples of the hydrophilic polyrner include hydroxypropyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, etc.
2l62o~
~ WO 94/27140 - PCT/GB94/01011 The e~throcyte aggregating agent is suitably a water-soluble and organic solvent-soluble component, typically polymeric, which can easily be released and dissolved into blood plasma when it is brought into contact with the blood. Such a material induces and accelerates erythrocvte aggregation as rouleaux at the surface of the membrane, thus preventing the erythrocytes from passing through the membrane. Examples of the erythrocyte aggregating agent which act as a mobile erythrocyte aggregating agent include dextran and positively charged polymers such as polylysine salts, polybrene (that is, hexamethrine bromide), protamine, etc.
It is l~,efelled that the e~ythrocyte aggregating agent is more soluble in water than the hydrophilic polymer, in order that the erythrocyte aggregating agent is the first component to dissolve and can rapidly induce formation of the rouleaux.
The relative amounts of the three components are chosen on the basis of the desired properties of the membrane such as the porosity and hydrophobicity. A ylert;lled range for the weight ratio (hydrophobic polymer): (hydrophilic polymer) is from 3:1 to 1:3, more yrefelably from 2:1 to 1:2, and most yrerel~bly from 3:2 to 2:3. Thus, the typical membrane contains about equal amounts of the two types of polymer.
The erythrocyte aggre~ing agent is usually a minor component of the membrane, and yrefclably comprises from 5 to 45 % of the membrane, more yrefel~bly from 10 to 40 % and most p~r~l~bly from 25 to 35 %.
Thus, the typical membrane contains about 30 % of the erythrocyte aggregating agent.
Other components may be included in the membrane, such as surfactants to improve wetting, or plasticizers such as dioctyl phth~l~te.
In the l,re~lled membrane there is a generally homogenous distribution of heterogenous polymeric components with the mobile erythrocyte aggregating agent located inside a polymeric network of interconnecting porous pathways through the membrane. In l"e~lled embodiments, the pore diameters are in the range l to 15 ,um, more ~refel~bly 3 to 15 ,um.
One of the features of this invention which ~ tin~ hes this membrane system from other membranes is the characteristic of sep~ g WO 94/27140 21~ 2 ~ 4 5 6 PCT/GB94/01011 erythrocytes from whole blood even when the pore size of the membrane is significantly larger than the maximum diameter of the erythrocytes.
A proposed mech~ni~m for erythrocyte separation by the preferred membrane is described as follows, though we are not bound by this theory.
After whole blood is brought into contact with the membrane, the plasma wets across the membrane surface and soaks into the hydrophilic polymer, m~kin~ it swell to reduce the membrane pore size. At this initial stage, the erythrocytes are held outside the membrane pores, transport of plasma through the membrane is relatively slow, and the erythrocyte aggregating agent is mobilized and forced out from the membrane pores into the plasma. The mobile erythrocyte aggregating agent has high solubility in the aqueous phase and dissolves into the plasma faster than the hydrophilic polymer, ini~i~ting the formation of rouleaux. The plasma then wets through the hydrophilic material to give more swelling and to release more erythrocyte aggregating agent which accelerates the process of erythrocyte rouleaux formation, to stop the erythrocytes from penetrating the membrane. W~en most of the erythrocyte aggregating agent has dissolved7 the hydrophilic material starts to dissolve into the plasma, effectively opening up the membrane pores to allow faster transport of the plasma. At this stage, the size of the membrane pores may be larger than that of an individual erythrocyte, but by this time most erythrocytes have become erythrocyte rouleaux and the membrane is therefole still capable of holding the erythrocytes outside the membrane pores to prevent fouling of the membrane pores which occurs with most of the convenhonal procedures for membrane se~ lion.
The membranes of the present invention are especially suited for use in electrode test strips for an electrochemical sensor. Such a sensor, for example for amperometric or potentiometric detection~ ~pically employs a dry throw-away electrode test stnp . The electrodes ~refef~bly comprise electrode areas formed for instance by screen printing or other suitable technique. Reference is made to EP-A 127958, 184895, 230786, among other published European Patent Specifications in the name of MediSense, Inc., formerly known as Genetics International Inc., and the disclosures of these three European Patent Specifications are incorporated for their teaching of m~nllf~cturing methods and constructional features. The %1~2Q~
WO 94/27140 7 . PCT/GB94/01011 membrane of this inventiOn for an amperometnc electrode test strip usuallv has a thickness in the range 20 to 50 ~m.
The membrane is preferably formed in situ on the strips.
As an example of the in situ procedure, the membrane can be made by spray casting. With c~ctin~ the membrane will be formed in intim~te contact with the strip surface. There are other advantages in casting or coating of the polymer solution directly on the strip surface by spraving a polymer solution followed by evaporation of the solvents. With such a technique, it is possible to control the porosity of the membrane, notably by selection of solvents and spraying conditions. Moreover, the possibility of deactivating the enzymes can be greatly reduced, since unlike dip-coating the polymer solution re~chin~ the electrode surface contains lower levels of solvents.
The membrane components are dissolved in a mixed solvent and mLxed thoroughly. Depending on the characteristics of the polymeric materials, the membrane c~stin~ techniques and the desired membrane morphology, di~elent solvent systems are used. The polymers, the mixed solvent system, the mixin~ ratio and the membrane deposition method and conditions are usually selected so that a membrane is obtained which is characterised by its homogeneity and the luli~o~m distribution of micropores, ~refer~bly within the size range 1 to lS~m. The porosity will typically reflect the spraying llict~nce, the spray pressure, and the volatilityof the solvents. In particular, larger pores are produced as the spraying distance is re-lllce~l and, correspondingly, smaller pores are produced as the spraying di~t~nce is increased. The thickn~ss of the membrane can be controlled as desired and depends on the polymeric materials, the concentration of these materials in the continuous medillm and the manufacturing conditions.
The resultant ~refe~ed membrane structure is distin~iche-l by the distribution of three polymeric components. The hydrophobic polymer forms the porous structure, and the other polymers coat the surface of this r structure. In this way, the blood sample spreads rapidly over the membrane. The rapid transport is facilitated by the porous structure and hydrophilic properties of the surfaces. In other words, the hydrophillic -WO 94/27140 2 ~ 2 a ~ 8 PCT/GB94/01011 functional groups facilitate the wetting of the surface while the rnicropores provide a path for the diffusing con~titl-ents.
Techniques apart from spray casting can be used. For instance, the membrane can be separately made as a sheet for fixing to strips duIin~
manufacture of the strips. As an example of the separate sheets, the membrane can be made by dip coating of a porous support, for example a mesh such as nylon mesh, or a web of non-woven polyester. The porosity will typically reflect the relative amounts of the membrane components, the choice of solvent, and processing such as water-rinsing. The polymeric components can be sprayed or applied by inkjet or pulsejet printing, needle dosing, rollercoating, printing, and similar techniques.
Membrane solutions can be cast onto the tranquil surface of a bath of non-solvent for the membrane polymers. A polyrneric membrane forms when solvents evaporate from the membrane solution. The final membrane is obtained by removing the polymeric membrane from the non-solvent bath and drying it in air.
Membrane solutions can also be cast onto the surface of glass plate to allow the solvents to evaporate into the air. A polymeric membrane is obtained when most solvents evaporate. The dried membrane can easily be detached from the glass plate with the help of a silicon spray on the glass plate before c~ctin~
Membrane solu~ions can also be ~iirec~ly cast onto the object surface using printing techniques.
The Drawings The invention will be further described by way of exan~ple with refel ~nce to Figures 1 to 4 of the accompanying drawings, in which:
Figure 1 shows in diagr~mm~hc cross-section a first embodiment of the invention;
Figure 2 shows an exploded perspective view of a second embodiment;
~ WO 94/27140 ~16 2 0 ~ 5 PCT/GB94/01011 Figures 3 and 4 shows al,palalUs for spray c~tinE employed in the F,x~mples;
Figure S shows in diagr~mm~tic cross-section a third embodiment of the invention; and Figure 6 shows in diagr~rnm~tic cross-section a fourth embodiment of the invention.
.
Figure 1 shows a dry disposable electrode test strip 10 for use as part of an amperometric test sensor. A PVC substrate 1 1 carries carbon tracks 12 overlain with silver tracks and coated to form a working electrode 13 and a reference electrode 14 which are covered by a membrane 15. The carbon tracks form contacts for connection of the strip to readout al~a~ s, and are coated with a silver conductive ink to improve the conductivity of the carbon. In use, a drop of blood 16 is applied to the surface of the m~mbrane.
Figure 2 shows a second embo-liment of the invention. A PVC substrate 21 of a test strip 20 carries carbon tracks 22 overlain with silver tracks 23 and coated to form a working electrode 24 and a fe~lence electrode (not visible) which are covered by a membrane 25. In this case the test strip 20 has an outer coat 26 as a non-porous humidity barrier. An aperture 27 in the humidity barrier forrns a target s~mple application zone, for the application of whole blood. Blood applied to zone 27 wicks under coat 26 through a pe~ ble m~tP~ 28 to m~mhrane 25 where plasma components rapidly penetrate and wet the electrodes.
The confi~lration of Figure 2 not only acts as a barrier to red blood cells, but also re~1lces the effect of en~/iro~ ental factors on the strip response.
In Figures 3 and 4, a~au~ s for spray c~cting of the membranes employs an air brush 30, driven from a compressor 31. In this in~t~nce, the air brush 30 was stationary and a card 32 of multiple electrode strips was mounted on a metal rail 33 driven by an adjustable motor 34. The electrode card 32 was covered by a stencil 35 to give deposition of the membrane polymer solution onto the intended electrode sen~ing area.
WO 94/27140 216 2 0 ~ ~ lo PCT/GB94/01011 In the embo~liment of Figure 5, the construction is as shown in Figure 1, except for the provision of the membrane in the form of a nylon mesh 36 dip-coated with polymer solution.
In the embodiment of Figure 6, the construction is as shown in Figure 1, except for the provision of the membrane as two polymer layers 37, 38.
Examples of The Invention Example 1 Electrode test strips for cholesterol were made in accordance with EP-A
230786, using screen printing. In this m~nllf~ctnring process, multiple electrodes were screen printed onto a large sheet of carrier material, which was then subdivided to give individual test strips. The screen-printing process comprises the following steps;
a) printing of a conductive tracking b) printing of a working electrode c) printing of a reîerence electrode, and d) printing of a dielectric in~nl~t~on The working electrode was prepared from commercially obtained horse radish pero~ se, cholesterol oxidase, cholesterol esterase, sodium cholate and binder. These were reco~ (e~ in an imitl~7.ole buffer mLx of pH 7 for 2 hours prior to the addition of finely divided carbon and 1,1'-dirnethylferrocene ethanolamine as me~ tor. The working electrode was screen plinted onto the l~rep~ ted carbon track. The mix was allowed to dry.
Batches of the electrode test strips were provided with membranes in accordance with the present invention. The reslllt~nt electrodes collfolllled with the construction shown in Figure 1. The conductive carbon tr~çkinE for each electrode was screen-printed onto the surface of the substrate in two conductive tracks of 45 mm by 2 mm, with a separation of 3 mm. The membrane was spray coated over the electrodes.
Where desired, the test strips can be with the construction shown in Figure ~i 620~
2, with a surfactant coated nylon mesh as permeable material 28 and a humidity overlayer 26 applied over the membrane.
For the spray-casting of the membrane, polymer solutions were spray-cast onto the surface of the electrodes as part of the m~nllf~ctuIing process.
The step of spray-c~tin~ was carried out using the apparatus of Figures 3 and 4, with an air brush (Badger Model 200, Badge Air-Brush Co., Illinois), driven from an oil-free air compressor (Pioneer 200, Clark International, London). The distance between the spray nozzle of the air-brush 30 and the electrode card 32 and the vertical position of air-brush 30 was set up to be easily adjusted, it being recognised that this distance affects the evaporation of solvent and thus the structure of the cast membrane. The typical spray-casting parameters used for the membrane coating were as follows:
Distance between the spray nozzle and the targeted electrode surface:
18 cm Electrode movement: 125 cmlmin Number of spray passes: 2 A mlmber of polymeric materials were investigated for their suitability as the membrane materials for the membranes. T~e following polymeric materials showed particularly promi~in~ characteristics:
Hydrophobic polymer:
Cellulose acetate propionate ~CAP F.~ n Chemicals, Kingsport, Tennessee, USA) Poly(vinyl butyral) (B-72 or B-79, Butvar, Monsanto Ltd., St. Louis, Missoun, USA) Hydroxyethyl cellulose (Natrosol 250 mR, Aqualon UK Ltd., Chester, UK) Hydrophilic polymer:
Hydroxypropyl cellulose ~Klucel HPC L, Aqualon UK
Ltd., Chester, UK) WO 94/27140 PCT/GB94101011 ~
2162~45 12 Poly(vinyl alcohol) (Aldrich Chemicals Co. Ltd., Gillin~h~n~, Chester, UK) Erythrocyte aggregating agent:
Dextran 3759 (Sigma Chemical Co. Ltd., Poole, Dorset, UK) Ethyl acetate was found to be a possible solvent. However, CAP/HPC
solutions in ethyl acetate have a milky appearance and a second solvent is needed, in order to provide an entirely miscible polymer solution cont~inin~ CAP/HPC. Ethanol and meth2nol were found to suitable.
Methanol gives a true solution of CAP/HPC at a much smaller presence in the solvent lllixLule than does ethanol. It was ascertained that the optimal ~mount of methanol in the polymer solution was 8%. This amount of methanol when combined with 82% of ethyl ~cet~te, 5% of CAP and 5%
of HPC gives a clear solution of CAP/HPC with low viscosity and good processability.
A~lo~liate amounts for a 5% solution of each of the polymers CAP and HPC were added to the solvent ~xlule in a ball-millin~ jar. Complete solution of the polymers in the solvent ~ e took about 30 minlltes under stirring. An a~ u~liate arnount of dextran was milled in a mortar to reduce the particle size to around 50 ~m and then mixed into the polymer solution. This l~ e was then milled with ceramic milling balls until the dextran particle size fell below 20 ,~Lm. In the resl-lt~nt polymer rruxture, the ratio CAP: ~C: dextran was 3.6: 3.6: 0.7. Initially, this ure too high a viscosity for spray application, and the polymer solution/cornposition was then ~1ihltel1 with ethyl ~cet~te/meth~nol (90%/10%). The co~tin~ were deposited onto the electrode surfaces using the equipment. The membranes were then dried. The performance of the membrane-coated cholesterol electrodes were then assayed.
Drawing on this initial work, polyrner solutions co~ valious compositions of CAP, HPC, dextran, ethyl acetate and methanol were prepared. These polymer solutions were cast onto the sensing area of cholesterol electrodes. In general with the spray procedure, there was some difficulty in achieving reproducible homogenous coating.
From this work, the optimal formulation, which gave the best membrane morphology and membrane transport performance, is given in the following table.
Materials Composition(%) CAP 3.6 E~C 3.6 Dextran 0.7 Ethyl acetate 82.8 Methanol 9.3 The resultant mçmbrane had an average pore size of 4 ,um, as determined by sc~nnin~ electron microscopy.
In a side experiment, the formulation was spray coated onto filter paper and dried. A stainless steel weight with a drilled 4 mm central hole was put on the filter paper. The membrane-coated paper with weight were placed on a sheet of uncoated filter paper. A 15~1 blood sample was added to the hole and left for 15 secorlrl~. The underlying uncoated filter paper was then evaluated for erythrocyte break-through, and found to be straw coloured. This result indicates that only plasma passed through the membrane, with the main driving force being gravity.
In order to study the transport properties of the membrane cast on the electrode s~ ce, membld~c co~te~1 electrodes were ev~ te~l using blood samples. A range of blood samples with h~e ~ ocrits varying between 30% and 60% PCV (packed cell volume) and constant cholesterol were tested. Electrodes were either uIlcoated, or coated with of membrane either S,um or 10~un thick.
The i-t transients were recorded and integrated over 40 to 60 seconds.
The following data for di~,rent b~tches of electrodes were obtained:
m~tocrit regression -V-,lLC response slope regression CV(%) uncoated -0.355 0.817 2.56 coated (5~m) 0.026 0.029 8.86 coated (5,um) -0.076 0.227 2.74 WO 94/27140 7, ~ ~ % ~ ~5 14 PCT/GB94/01011 coated (10~Lm) -0.018 0.056 3.22 coated (10~m) 0.015 0.023 6.9 All of the electrodes with the membrane thus gave a negligible haematocrit effect.
Fx~mple 2 It was found that the morphology of the membranes of Example 1 was sometimes sensitive to the parameters associated with the spray operation.
Considering that an optimized industrial process needs relatively low sensitivity to the process parameters, alternative membrane formulations were designed.
A solvent blend which contains acetone, methanol and mesitylene was found to be more suitable. Acetone and methanol were used as solvents for CAP and HPC respectively. Acetone evaporates first into the air when the membrane solutions are cast onto the electrode surface. As a result of this acetone evaporation, CAP in the membrane solution is transformed from a gel-phase into a solid phase. The solid-phase CAP
forms the skeleton of the membrane structure. The ~leci~ Lion of HPC
is slower than that of CAP bec~-lse HPC is retained in methanol which evaporates slower than ~cetone. The.~fole, the CAP-~cetone system ~ives a ~ porous structure. The HPC deposits on the s~ ce of the primary membrane pores.
Mesityle~e was used as a pore-former in ~e membrane. Mesitylene is a non-solvent to the CAP, HPC and dextran. Mesitylene has a much higher boiling point than either acetone or methanol. Thus, it rem~in~ in the membrane for a longer time than acetone or methanol. This enables mesitylene to be a good former of secondary membrane pores.
A typical formulation for a membrane solution is as follows:
Cellulose Acetate Propionate 1.25% POLYMER 1 Klucel Hydroxypropyl Cellulose 1.25% POLYMER 2 Dextran MW 87,000 g/mol 0.25% POLYMER 3 ~ = ~ ==
2~6204~
Surfactant (Fluorad FC 1 70C, 3M Company Commercial Chemicals Division, St. Paul, Minnesota, USA) 0.25%
Acetone 43.5%
Methanol 43.5%
Mesitylene 1 0.0%
The resultant membrane when using a spraying dist~nce of 4.0 cm had an average pore size of 7 !lm, as determined by sc~nning electron mlcroscopy.
Apart from cellulose acetate propionate, there are many hydrophobic polymers with good solubility in organic solvents which can be used as the POLYMER 1 in the membrane form~ tion- These polymers include cellulose acetate, polyvinyl butyral, polystyrene, etc.
Alternatives to the hydroxypropyl cellulose, which can be used as the POLYMER 2 and have good solubility in organic solvents include polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl ~cet~te, etc.
There are ~ltç~ ~ve polymers apart from dextran, which can be used as POLYMER 3 in the membrane formulations. These polymers should have high molecular weights, good hydrophilicity and should be soluble in organic solvents. Some positively cllalged polymers with good hydrophilicity and with modest to good solubility in organic solvents can also be used. These alternatives to dextran include polylysine, polybrene, .ot~i~le, etc.
F~r~mple 3 The main advantage of plasma se~tion is a reduction in the red cell elrere.~ce on the sensor electrodes. This illle-r~rence is due to diffilsional limit~tion and some interfering reaction. Wi~ increasing haematocrit there is a reduction response at the sensor electrode at a constant analyte concentration. With an effective red cell exclusion membrane a reduced haematocrit response is expected.
wo 94/27140 21 6 2 04 5 16 PCT/GB94101011 Electrode test strips for glucose were made in accordance with EP-A
127958, using screen printing. The m~nl;~f~cturing process was much the same as that described in Exarnple 1 for the m~n~lf~cture of electrode test strips for cholesterol, except that the working electrode was prepared from commercially produced glucose oxidase and binder. These were reconstituted in BES buffer pH 7.4 for 2 hours prior to addition of ultrafine carbon and l,l'-dimethylferrocene ethanolamine as mediator.
Batches of the strips were sprayed at different distances with the formulation of Example 2 to form membranes of di~rellt pores sizes.
The following results for glucose sensors in accordance with EP-A
127958, with and without membranes, show the relative reduction in h~em~tocrit response, corrected for glucose sensitivity.
Spraying Membrane Relative E~em~tocrit Distance (cm) Pore Size (,um) Response (%) Uncoated 1 00 electrodes Membrane coated 3.5 10 45.4 electrodes Membrane coated 4.0 7 23.3 electrodes Membrane coated 5.5 2 33.1 electrodes In this experiment the 7 ~m pore size membrane gave the greatest reduction in relative h~m~tocrit sensitivity.
Example 4 The dip-coating technique was also used to produce membranes for test strips for glucose sensors in accordance with EP-A 127958. The construction of the resultant test strip is illustrated in Figure 5.
Nylon mesh was dipped into the polyrner solutions to allow the nylon mesh to be coated with the polymer solution. The coated nylon mesh was then removed from the polymer solution and allowed to dry. These 21620~
procedures gave a ullifol~ polymeric membrane on the nylon mesh. In fine-tuning the membrane morphology, rinsing and then washing of the dip-coated nylon mesh with water, to give more porous membrane morphology was carried out.
A typical polymer solution used for dip-coating the nylon mesh is givenbelow, and cont~ined CAP, ~'C, tetrahydrofuran (T~), cyclohexanone and dioctyl phth~1~te. In this solution, CAP, the major membrane material, formed the rigid skeleton of the membrane system. HPC
contributed to the formation of microporous structure and to the hydrophilicity of the membrane system. By altering the ratio of CAP and HPC in the polymer solution, it is possible to control the porosity of the membrane structure. THF is the major solvent used in the polymer solution. T~ plays an important role in inllur.in~ the L~ ;on of a microporous m~.mbrane structure. Under the e~c.;... ~l~1 conditions, it was found that the evaporation rate of the THF was high, and there was some difficulty in obt~inin~ membranes of w~irOllll thickness.
Cyclohexanone was used as a minor solvent for CAP and for HPC. By altering the ratio of the THF and cycloh~x~none, the solvent evaporation rate was controlled to a s~ti~f~ctory degree to achieve a membrane of accurate thiçkness. The porosity increæed with increasing amounts of cyclohe~none. Dioctyl phth~l~te was used to provide plasticity to the membrane s¢ucture. This was bec~llse a membrane con~i~tinE of CAP
and HPC can be brittle. Dioctyl phth~1~te wæ çhosen in this context bec~llce its physicochemical nature allows it to assist the diffusion of plasma through t~e membrane.
Nylon mesh was dipped for a few seconds into the polymer solutions.
The mesh was then rinsed with water at ambient temp~lule for 5 seconds to induce the precipitation of CAP and the extraction of part of the HPC
from the membrane assembly. The system was then dip-coated with a mixture of !% dextran, 1% surf~ct~nt and water at ambient ~empc~ re, and dried in air. In the dip-co~in~ technique used in this study, the water rinse was designed to induce the precipila~ion of CAP and to dissolve part of the HPC cont~ined in the cast polymer solution, to improve the efficiency of plasma transport. The water rinse helps the forrnation of the porous swcture in the membrane, to provide desired hydrophilicity. The WO 94/27140 21~ 6 2 0 ~ ~ 18 PCT/GB94/01011 coated nylon mesh was then fixed onto the electrode surface of both the cholesterol electrodes and the glucose electrodes.
Polymeric materials were investigated for their suitability as ingredients in a dip-coating formulation. A prefelled dip-coating membrane formulation was found to be as follows:
Polymer %
CAP 2 Polymer 1 E~'C 2 Polymer 2 THF 85 Solvent 1 Cyclohexanone 4 Solvent 2 Dioctyl phth~l~te 7 Additive The surface morphology of a typical dip-coated nylon mesh membrane was ~x~...;.,ed by sc~nning electron microscopy, showing porous structures with an average pore size of 4 ~lm.
Screen printed sensors for cholesterol were plc~alcd in accordance with EP-A 230786, with and without the dip-coated membrane.
On testing it was found that the cholesterol electrodes with membrane gave higher electrode cull~nls than the cholesterol electrodes without membrane, and higher values i-t integration.
From statistical analysis of the data, it was concluded that the me~llbla.le cholesterol electrodes have higher sensitivity to the cholesterol than do the ordinary cholesterol clc. lsodes. This is in-lic.~te-l by the higher slope of cholesterol calibration line for the membrane cholesterol electrodes (10.539) than that for the ordill~y cholesterol electrodes (5.412).
Tests for the h~P.~ ocrit effect were carried out on the ordi,l~y cholesterol electrodes and the cholesterol electrodes covered with dip-coated membranes in order to evaluate the ability of the membrane to separate erythrocytes from blood samples. The blood samples were as follows:
Sample 1: E~em~tQcrit level = 36%
æ~o4~
Cholesterol concentratiOn = 6.98 mM.
Sample 2: ~em~tocrit level = 44%
Cholesterol concentration = 6.98 mM.
Sample3: Haematocr~tlevel = 54%
- Cholesterol concentration = 6.98 mM.
The i-t transients were obtained and integrated over the period 27~0 seconds, in order to carry out haematocrit effect analysis. The average statistical pararneters for the tested batch associated with the haematocrit effect lines are given in the next table.
ElectrodeType Slope s Intercept ~i R
No Membrane -0;137 0.051 21.725 2.306 0.5982 Membrane -0.072 0.124 19.648 5.478 0.2510 From the table, it can be concluded there is a reduced h~em~tocrit effect using the dip-coated nylon meehes. There is a re-lnction of the absolute value ofthe slope ofthe h~P..,~tocrit effect lines from 0.137 (for t_e or~li,l~y cholesterol electrodes) to 0.0721 (for the mçmbrane-treated cholesterol electrodes).
Fx~mple 5 Dextran has limite~l solubility in many organic solvents. Another ~ploach to the incl~leion of dextran in the membrane assemblies is spray-c~etin~ of a two-layer, membrane assembly. The idea involves spray-c~etin~ a polymer solution co~ CAP and HPC as the first membrane layer followed by spray-c~etin~ a polymer solution co~ dextran on top of the first membrane layer. The construction of the resl-lt~nt test strip is illustrated in Figure 6.
The hydrophobic polymer and the hy~o~ ilic polyrners can be prepared for the c~tin~ of the first membrane layer. The erythrocyte aggregating agent material, dextran, can be dissolved in ethylene glycol to give the polymer solution for the casting as the second membrane layer. Polymer solutions either cont~ining both ~'C and dextran were l,re~aled. Since ethylene glycol has too low a volatility, a l~ixLule of ethanol and ethylene glycol was use~als ~e so~vent in preparation of the solution for the second membrane layer.
Membranes with different contents of dextran were prepared. These membranes consisted of two membranes layers each approximatelv 5 to 10 ~m in thickness. The first membrane layer contained 50% of CAP and 50% of HPC. The second membrane layer cnn~i~ted of dextran and HPC.
The composition of dextran in the second layer was varied to allow assessment of the function of dextran in the separation of erythrocvtes.
The fo~ tions of the polymer solution for c~stin~ of the second membrane layer are given in the next table. These polymer solutions contain 90% of ethylene glycol.
Solutions Compositions (%) Dextran HPC
0.0 10.0 2 2.5 7.5 3 5.0 5.0 4 7.5 2.5 0.0 The cholesterol electrodes, coated with the CAP/HPC (50%:50%, first layer) and dextran/~C (secon~ layer), were tested for their ef~iciency in se~ g e~rocytes and in tran~o~ g cholesterol.
Whole hllm~n blood samples were used, as follows:
Sample 1: ~tn~tocrit level = 32%
Sample 2: E~m~tocrit level = 34%, Sample 3: H~tn~tocrit level = 48%.
The i-t transients were integrated over the period of 15-30 seconds, and from ~e SD values, it can be concluded that the i-t transients obtained have s~ti~f~ctory overall reproducibility.
The h~em~tocrit effect lines were plotted, giving the following data.
2~ q5 WO 94/27140 21 ` PCT/GB94/01011 Dextran (%) Slope ~s Intercept ~i R
- 0.0 -0.427 0.045 30.055 1.886 0.984 2.5 -0.156 0.048 20.028 1.971 0.916 5.0 -0.003 0.141 17.350 5.751 0.010 7.5 -0.044 0.120 18.987 4.899 0.180 10.0 -0.052 0.025 14.360 1.040 0.822 These results shown the ability of dextran to facilitate the exclusion of eIythrocytes, as demonstrated by the decrease in absolute value of the slopes from 0.427 to 0.003.
ELECTROCHEMICAL SENSORS
Introduction The present invention relates to electrochemical sensors, and more particularly but not exclusively to electrochemical biosensors. The present invention further relates to a method of manufacture of test strips for use in such sensors.
Background of the Inventio~
There is an increasing public awareness of the diagnostic significance of levels of components in the blood and other body fluids, and many sensors are designed for non-expert use. A particular goal is the provision of electrochemical sensors which do not require elaborate preparation of a test sample, and can rapidly give a result merely by application of the body fluid to a test strip. Good sensitivity is achieved usually with a biochemically specific reaction, such as by enzymatic catalysis of a reaction of the component to be detected. The reaction results in transfer of charge which can be q~l~lit~tively or 4~ ely detected, for instance by an amperometric procedure.
Amperometric biosensors for p~"rwlll~.lg diagnostic tests for components of body fluids are described, for exarnple, in US Patent 4545382, European Patent 127958 and European Patent 351891. Such devices offer the facility for rapid, convenient and specific measurements of analyte components in blood by lay users, and a sensor for glucose is commercially available as the MediSense ~ ExacTech g) sensor.
.
Whole blood is a complex, predomin~tely aqueous mixture cont~inin~
dissolved gases, simple dissociated and hydrated ions, materials in colloidal or other form of solution, small scale cellular debris, and living cellular components including red blood cells, the erythrocytes. It is WO 94/27140 21 ~ 2 Q~ 5 2 PCT/GB94/01011 sometimes difficult to achieve reproducible analytical results with electrochemical sensors when using whole blood samples. Varia~ions in red cell concentration, the h~em~tocrit, is the main contributor to inaccuracies in using whole blood samples for electrochemical sensors.
Accordingly, there is a need to develop improved electrochemical sensors which are less dependent on the h~em~tocnt of the blood. To this end, there have been proposals for overlay membranes which serve to exclude erv~rocytes so that the sensor itself is only contacted by blood plasma.
Illustrative examples of proposals for erythrocyte exclusion membranes are to be found in published EP-A 289269 and other patent literature.
There are difficulties in developing a s~ti~f~etory ery~rocyte exclusion membrane suited for test strips such as amperometric electrode test strips.
A hurn~n erythrocyte is deformable in vivo to pass through lllmin~l di~meters as small as 2 or 3 ,um, and thus membranes of this porosity are ineffective, either because the erythrocytes leak through by deformation or bec~llee the erythrocytes plug the pores to prevent passage of the plasma.
Where the porosity is further re~llce~l, the transport of plasma is difficult.
In this respect, the typical volume of the blood sample for an amperometric glucose test is only 20 ~1 and yet gravity has to provide the principal driving force, with capillary forces providing only a secondary driving force. Given the goal of m~ or redueing me~ellrement times, where the period for a complete glucose test is typically 30 seconde, rapid transport of the plasma through the membrane is needed.
Thus, the transport of the plasma requires an open membrane structure, while the sep~dlion of erythrocytes ~ n~le a closed membrane structure. In t~e light of these contradictory requirements, it becomes clear that conventional membrane systems are not entirely suitable.
US Patent 5,055,195 describes the use of retention substrates which bring about strong co~ hon of blood so that the corpuscular components are effectively retained in a paper or glass fibre fleece and are sepalated from the plasma. This object is achieved by using retention substrates which contain two strongly polar groups which are connected by a non-polar bridge. The retentio~ substrates are preponderantly dyestuffs, and they bring about random clurnping.
2~
Objects of the Invention An object of the present invention is provide an improved erythrocyte exclusion membrane for an electrochemical sensor. In this respect, it is an object to provide an improved porous erythrocyte exclusion membrane which permits rapid transport of plasma through the membrane, while subst~nti~lly excluding the passage of erythrocytes. A particular object is the provision of a disposable single-use electrode test strip for an amperometric biosensor, for use with a sample of whole blood, which is less dependent on the haematocrit of the blood.
A related object is to provide a new method for the m~nllf~cture of test strips.
S~lmm~ry of the Invention According to the present invention, there is provided an erythrocyte exclusion membrane comprising a porous matrix including an erythrocyte aggregating agent.
The erythrocyte aggregating agent is an agent which can induce the formation of erythrocyte aggregates known as rouleaux. Such rouleaux have a diameter of typically 50 to 100 times that of an individual e~throcyte, and are not r~n~lom clumps. Accordingly, with the inclusion of the erythrocyte aggregating agent, the porosity of the membrane can be such that individual erythrocytes might otherwise pass through the matrix, but rouleaux can not pass through the matrix. The ery~rocyte aggregating agent is present at or migrates to the surface of the membrane to bring about formation of the rouleaux. In this way, the erythrocytes are held outside the membrane pores, allowing effective transport of the plasma with separation ~om the erythrocytes.
Thus, the present invention provides a test strip for an electrochemical sensor for contact with whole blood in order to effect an electrochemical measurement. The test strip has an exclusion layer in the form of a porous membrane with an erythrocyte aggregating agent. The membrane excludes red blood cells from contact with the sensing electrodes by WO 94/27140 ~ 2 ~ 4 4 PCT/GB94/01011 aggregating them at the surface of the membrane and excluding them as e~hrocyte rouleaux. By virtue of the presence of the exclusion laver, the sensing electrodes are exposed only to plasma, so that the red blood cells can not i~llelfere. In this way, reproducible results are more easily achieved, even for disposable test strips made in high volume and at low cost.
Preferred Embodiments The l,refelled porous matrix ofthe polymeric membrane mainly consists of a water-insoluble hydrophobic polymer so that this matrix will not be si~nificantly altered by the water present in whole blood. However, membranes con~i~ting of such material have poor wethng ability. In order to obtain effective plasma transport through the membrane pores, the porous hydrophobic matnx ~fe,ably incorporates a hydrophilic polymer.
A ,~)rer~lled membrane thus comprises at least three groups of polymeric materials, namely a hydrophobic polymer, a hydrophilic polymer, and a mobile erythrocyte aggregating agent.
The hydrophobic polymer is a water-insoluble but organic solvent-soluble membrane-forming polymer which provides the desired porous membrane structure. Such polymers are well known and typically contain hydrophobic functional groups at a ~lomin~nt level, though a rninor proportion of hydrophilic fimctional groups can be present. F.~mples of the hydrophobic polymer include cellulose acetate propionate, cellulose acetate, polyvinyl butyral, polystyrene, etc.
The hydrophilic polymer is a water-soluble and organic solvent-soluble polvmer which provides good membrane permeability to plasma and especially dissolved analytes in the plasma. Such polymers are well known and typically contain hydrophilic fi~nctional groups at a dominant level, though a minor proportion of hydrophobic functional groups can be present. Examples of the hydrophilic polyrner include hydroxypropyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, etc.
2l62o~
~ WO 94/27140 - PCT/GB94/01011 The e~throcyte aggregating agent is suitably a water-soluble and organic solvent-soluble component, typically polymeric, which can easily be released and dissolved into blood plasma when it is brought into contact with the blood. Such a material induces and accelerates erythrocvte aggregation as rouleaux at the surface of the membrane, thus preventing the erythrocytes from passing through the membrane. Examples of the erythrocyte aggregating agent which act as a mobile erythrocyte aggregating agent include dextran and positively charged polymers such as polylysine salts, polybrene (that is, hexamethrine bromide), protamine, etc.
It is l~,efelled that the e~ythrocyte aggregating agent is more soluble in water than the hydrophilic polymer, in order that the erythrocyte aggregating agent is the first component to dissolve and can rapidly induce formation of the rouleaux.
The relative amounts of the three components are chosen on the basis of the desired properties of the membrane such as the porosity and hydrophobicity. A ylert;lled range for the weight ratio (hydrophobic polymer): (hydrophilic polymer) is from 3:1 to 1:3, more yrefelably from 2:1 to 1:2, and most yrerel~bly from 3:2 to 2:3. Thus, the typical membrane contains about equal amounts of the two types of polymer.
The erythrocyte aggre~ing agent is usually a minor component of the membrane, and yrefclably comprises from 5 to 45 % of the membrane, more yrefel~bly from 10 to 40 % and most p~r~l~bly from 25 to 35 %.
Thus, the typical membrane contains about 30 % of the erythrocyte aggregating agent.
Other components may be included in the membrane, such as surfactants to improve wetting, or plasticizers such as dioctyl phth~l~te.
In the l,re~lled membrane there is a generally homogenous distribution of heterogenous polymeric components with the mobile erythrocyte aggregating agent located inside a polymeric network of interconnecting porous pathways through the membrane. In l"e~lled embodiments, the pore diameters are in the range l to 15 ,um, more ~refel~bly 3 to 15 ,um.
One of the features of this invention which ~ tin~ hes this membrane system from other membranes is the characteristic of sep~ g WO 94/27140 21~ 2 ~ 4 5 6 PCT/GB94/01011 erythrocytes from whole blood even when the pore size of the membrane is significantly larger than the maximum diameter of the erythrocytes.
A proposed mech~ni~m for erythrocyte separation by the preferred membrane is described as follows, though we are not bound by this theory.
After whole blood is brought into contact with the membrane, the plasma wets across the membrane surface and soaks into the hydrophilic polymer, m~kin~ it swell to reduce the membrane pore size. At this initial stage, the erythrocytes are held outside the membrane pores, transport of plasma through the membrane is relatively slow, and the erythrocyte aggregating agent is mobilized and forced out from the membrane pores into the plasma. The mobile erythrocyte aggregating agent has high solubility in the aqueous phase and dissolves into the plasma faster than the hydrophilic polymer, ini~i~ting the formation of rouleaux. The plasma then wets through the hydrophilic material to give more swelling and to release more erythrocyte aggregating agent which accelerates the process of erythrocyte rouleaux formation, to stop the erythrocytes from penetrating the membrane. W~en most of the erythrocyte aggregating agent has dissolved7 the hydrophilic material starts to dissolve into the plasma, effectively opening up the membrane pores to allow faster transport of the plasma. At this stage, the size of the membrane pores may be larger than that of an individual erythrocyte, but by this time most erythrocytes have become erythrocyte rouleaux and the membrane is therefole still capable of holding the erythrocytes outside the membrane pores to prevent fouling of the membrane pores which occurs with most of the convenhonal procedures for membrane se~ lion.
The membranes of the present invention are especially suited for use in electrode test strips for an electrochemical sensor. Such a sensor, for example for amperometric or potentiometric detection~ ~pically employs a dry throw-away electrode test stnp . The electrodes ~refef~bly comprise electrode areas formed for instance by screen printing or other suitable technique. Reference is made to EP-A 127958, 184895, 230786, among other published European Patent Specifications in the name of MediSense, Inc., formerly known as Genetics International Inc., and the disclosures of these three European Patent Specifications are incorporated for their teaching of m~nllf~cturing methods and constructional features. The %1~2Q~
WO 94/27140 7 . PCT/GB94/01011 membrane of this inventiOn for an amperometnc electrode test strip usuallv has a thickness in the range 20 to 50 ~m.
The membrane is preferably formed in situ on the strips.
As an example of the in situ procedure, the membrane can be made by spray casting. With c~ctin~ the membrane will be formed in intim~te contact with the strip surface. There are other advantages in casting or coating of the polymer solution directly on the strip surface by spraving a polymer solution followed by evaporation of the solvents. With such a technique, it is possible to control the porosity of the membrane, notably by selection of solvents and spraying conditions. Moreover, the possibility of deactivating the enzymes can be greatly reduced, since unlike dip-coating the polymer solution re~chin~ the electrode surface contains lower levels of solvents.
The membrane components are dissolved in a mixed solvent and mLxed thoroughly. Depending on the characteristics of the polymeric materials, the membrane c~stin~ techniques and the desired membrane morphology, di~elent solvent systems are used. The polymers, the mixed solvent system, the mixin~ ratio and the membrane deposition method and conditions are usually selected so that a membrane is obtained which is characterised by its homogeneity and the luli~o~m distribution of micropores, ~refer~bly within the size range 1 to lS~m. The porosity will typically reflect the spraying llict~nce, the spray pressure, and the volatilityof the solvents. In particular, larger pores are produced as the spraying distance is re-lllce~l and, correspondingly, smaller pores are produced as the spraying di~t~nce is increased. The thickn~ss of the membrane can be controlled as desired and depends on the polymeric materials, the concentration of these materials in the continuous medillm and the manufacturing conditions.
The resultant ~refe~ed membrane structure is distin~iche-l by the distribution of three polymeric components. The hydrophobic polymer forms the porous structure, and the other polymers coat the surface of this r structure. In this way, the blood sample spreads rapidly over the membrane. The rapid transport is facilitated by the porous structure and hydrophilic properties of the surfaces. In other words, the hydrophillic -WO 94/27140 2 ~ 2 a ~ 8 PCT/GB94/01011 functional groups facilitate the wetting of the surface while the rnicropores provide a path for the diffusing con~titl-ents.
Techniques apart from spray casting can be used. For instance, the membrane can be separately made as a sheet for fixing to strips duIin~
manufacture of the strips. As an example of the separate sheets, the membrane can be made by dip coating of a porous support, for example a mesh such as nylon mesh, or a web of non-woven polyester. The porosity will typically reflect the relative amounts of the membrane components, the choice of solvent, and processing such as water-rinsing. The polymeric components can be sprayed or applied by inkjet or pulsejet printing, needle dosing, rollercoating, printing, and similar techniques.
Membrane solutions can be cast onto the tranquil surface of a bath of non-solvent for the membrane polymers. A polyrneric membrane forms when solvents evaporate from the membrane solution. The final membrane is obtained by removing the polymeric membrane from the non-solvent bath and drying it in air.
Membrane solutions can also be cast onto the surface of glass plate to allow the solvents to evaporate into the air. A polymeric membrane is obtained when most solvents evaporate. The dried membrane can easily be detached from the glass plate with the help of a silicon spray on the glass plate before c~ctin~
Membrane solu~ions can also be ~iirec~ly cast onto the object surface using printing techniques.
The Drawings The invention will be further described by way of exan~ple with refel ~nce to Figures 1 to 4 of the accompanying drawings, in which:
Figure 1 shows in diagr~mm~hc cross-section a first embodiment of the invention;
Figure 2 shows an exploded perspective view of a second embodiment;
~ WO 94/27140 ~16 2 0 ~ 5 PCT/GB94/01011 Figures 3 and 4 shows al,palalUs for spray c~tinE employed in the F,x~mples;
Figure S shows in diagr~mm~tic cross-section a third embodiment of the invention; and Figure 6 shows in diagr~rnm~tic cross-section a fourth embodiment of the invention.
.
Figure 1 shows a dry disposable electrode test strip 10 for use as part of an amperometric test sensor. A PVC substrate 1 1 carries carbon tracks 12 overlain with silver tracks and coated to form a working electrode 13 and a reference electrode 14 which are covered by a membrane 15. The carbon tracks form contacts for connection of the strip to readout al~a~ s, and are coated with a silver conductive ink to improve the conductivity of the carbon. In use, a drop of blood 16 is applied to the surface of the m~mbrane.
Figure 2 shows a second embo-liment of the invention. A PVC substrate 21 of a test strip 20 carries carbon tracks 22 overlain with silver tracks 23 and coated to form a working electrode 24 and a fe~lence electrode (not visible) which are covered by a membrane 25. In this case the test strip 20 has an outer coat 26 as a non-porous humidity barrier. An aperture 27 in the humidity barrier forrns a target s~mple application zone, for the application of whole blood. Blood applied to zone 27 wicks under coat 26 through a pe~ ble m~tP~ 28 to m~mhrane 25 where plasma components rapidly penetrate and wet the electrodes.
The confi~lration of Figure 2 not only acts as a barrier to red blood cells, but also re~1lces the effect of en~/iro~ ental factors on the strip response.
In Figures 3 and 4, a~au~ s for spray c~cting of the membranes employs an air brush 30, driven from a compressor 31. In this in~t~nce, the air brush 30 was stationary and a card 32 of multiple electrode strips was mounted on a metal rail 33 driven by an adjustable motor 34. The electrode card 32 was covered by a stencil 35 to give deposition of the membrane polymer solution onto the intended electrode sen~ing area.
WO 94/27140 216 2 0 ~ ~ lo PCT/GB94/01011 In the embo~liment of Figure 5, the construction is as shown in Figure 1, except for the provision of the membrane in the form of a nylon mesh 36 dip-coated with polymer solution.
In the embodiment of Figure 6, the construction is as shown in Figure 1, except for the provision of the membrane as two polymer layers 37, 38.
Examples of The Invention Example 1 Electrode test strips for cholesterol were made in accordance with EP-A
230786, using screen printing. In this m~nllf~ctnring process, multiple electrodes were screen printed onto a large sheet of carrier material, which was then subdivided to give individual test strips. The screen-printing process comprises the following steps;
a) printing of a conductive tracking b) printing of a working electrode c) printing of a reîerence electrode, and d) printing of a dielectric in~nl~t~on The working electrode was prepared from commercially obtained horse radish pero~ se, cholesterol oxidase, cholesterol esterase, sodium cholate and binder. These were reco~ (e~ in an imitl~7.ole buffer mLx of pH 7 for 2 hours prior to the addition of finely divided carbon and 1,1'-dirnethylferrocene ethanolamine as me~ tor. The working electrode was screen plinted onto the l~rep~ ted carbon track. The mix was allowed to dry.
Batches of the electrode test strips were provided with membranes in accordance with the present invention. The reslllt~nt electrodes collfolllled with the construction shown in Figure 1. The conductive carbon tr~çkinE for each electrode was screen-printed onto the surface of the substrate in two conductive tracks of 45 mm by 2 mm, with a separation of 3 mm. The membrane was spray coated over the electrodes.
Where desired, the test strips can be with the construction shown in Figure ~i 620~
2, with a surfactant coated nylon mesh as permeable material 28 and a humidity overlayer 26 applied over the membrane.
For the spray-casting of the membrane, polymer solutions were spray-cast onto the surface of the electrodes as part of the m~nllf~ctuIing process.
The step of spray-c~tin~ was carried out using the apparatus of Figures 3 and 4, with an air brush (Badger Model 200, Badge Air-Brush Co., Illinois), driven from an oil-free air compressor (Pioneer 200, Clark International, London). The distance between the spray nozzle of the air-brush 30 and the electrode card 32 and the vertical position of air-brush 30 was set up to be easily adjusted, it being recognised that this distance affects the evaporation of solvent and thus the structure of the cast membrane. The typical spray-casting parameters used for the membrane coating were as follows:
Distance between the spray nozzle and the targeted electrode surface:
18 cm Electrode movement: 125 cmlmin Number of spray passes: 2 A mlmber of polymeric materials were investigated for their suitability as the membrane materials for the membranes. T~e following polymeric materials showed particularly promi~in~ characteristics:
Hydrophobic polymer:
Cellulose acetate propionate ~CAP F.~ n Chemicals, Kingsport, Tennessee, USA) Poly(vinyl butyral) (B-72 or B-79, Butvar, Monsanto Ltd., St. Louis, Missoun, USA) Hydroxyethyl cellulose (Natrosol 250 mR, Aqualon UK Ltd., Chester, UK) Hydrophilic polymer:
Hydroxypropyl cellulose ~Klucel HPC L, Aqualon UK
Ltd., Chester, UK) WO 94/27140 PCT/GB94101011 ~
2162~45 12 Poly(vinyl alcohol) (Aldrich Chemicals Co. Ltd., Gillin~h~n~, Chester, UK) Erythrocyte aggregating agent:
Dextran 3759 (Sigma Chemical Co. Ltd., Poole, Dorset, UK) Ethyl acetate was found to be a possible solvent. However, CAP/HPC
solutions in ethyl acetate have a milky appearance and a second solvent is needed, in order to provide an entirely miscible polymer solution cont~inin~ CAP/HPC. Ethanol and meth2nol were found to suitable.
Methanol gives a true solution of CAP/HPC at a much smaller presence in the solvent lllixLule than does ethanol. It was ascertained that the optimal ~mount of methanol in the polymer solution was 8%. This amount of methanol when combined with 82% of ethyl ~cet~te, 5% of CAP and 5%
of HPC gives a clear solution of CAP/HPC with low viscosity and good processability.
A~lo~liate amounts for a 5% solution of each of the polymers CAP and HPC were added to the solvent ~xlule in a ball-millin~ jar. Complete solution of the polymers in the solvent ~ e took about 30 minlltes under stirring. An a~ u~liate arnount of dextran was milled in a mortar to reduce the particle size to around 50 ~m and then mixed into the polymer solution. This l~ e was then milled with ceramic milling balls until the dextran particle size fell below 20 ,~Lm. In the resl-lt~nt polymer rruxture, the ratio CAP: ~C: dextran was 3.6: 3.6: 0.7. Initially, this ure too high a viscosity for spray application, and the polymer solution/cornposition was then ~1ihltel1 with ethyl ~cet~te/meth~nol (90%/10%). The co~tin~ were deposited onto the electrode surfaces using the equipment. The membranes were then dried. The performance of the membrane-coated cholesterol electrodes were then assayed.
Drawing on this initial work, polyrner solutions co~ valious compositions of CAP, HPC, dextran, ethyl acetate and methanol were prepared. These polymer solutions were cast onto the sensing area of cholesterol electrodes. In general with the spray procedure, there was some difficulty in achieving reproducible homogenous coating.
From this work, the optimal formulation, which gave the best membrane morphology and membrane transport performance, is given in the following table.
Materials Composition(%) CAP 3.6 E~C 3.6 Dextran 0.7 Ethyl acetate 82.8 Methanol 9.3 The resultant mçmbrane had an average pore size of 4 ,um, as determined by sc~nnin~ electron microscopy.
In a side experiment, the formulation was spray coated onto filter paper and dried. A stainless steel weight with a drilled 4 mm central hole was put on the filter paper. The membrane-coated paper with weight were placed on a sheet of uncoated filter paper. A 15~1 blood sample was added to the hole and left for 15 secorlrl~. The underlying uncoated filter paper was then evaluated for erythrocyte break-through, and found to be straw coloured. This result indicates that only plasma passed through the membrane, with the main driving force being gravity.
In order to study the transport properties of the membrane cast on the electrode s~ ce, membld~c co~te~1 electrodes were ev~ te~l using blood samples. A range of blood samples with h~e ~ ocrits varying between 30% and 60% PCV (packed cell volume) and constant cholesterol were tested. Electrodes were either uIlcoated, or coated with of membrane either S,um or 10~un thick.
The i-t transients were recorded and integrated over 40 to 60 seconds.
The following data for di~,rent b~tches of electrodes were obtained:
m~tocrit regression -V-,lLC response slope regression CV(%) uncoated -0.355 0.817 2.56 coated (5~m) 0.026 0.029 8.86 coated (5,um) -0.076 0.227 2.74 WO 94/27140 7, ~ ~ % ~ ~5 14 PCT/GB94/01011 coated (10~Lm) -0.018 0.056 3.22 coated (10~m) 0.015 0.023 6.9 All of the electrodes with the membrane thus gave a negligible haematocrit effect.
Fx~mple 2 It was found that the morphology of the membranes of Example 1 was sometimes sensitive to the parameters associated with the spray operation.
Considering that an optimized industrial process needs relatively low sensitivity to the process parameters, alternative membrane formulations were designed.
A solvent blend which contains acetone, methanol and mesitylene was found to be more suitable. Acetone and methanol were used as solvents for CAP and HPC respectively. Acetone evaporates first into the air when the membrane solutions are cast onto the electrode surface. As a result of this acetone evaporation, CAP in the membrane solution is transformed from a gel-phase into a solid phase. The solid-phase CAP
forms the skeleton of the membrane structure. The ~leci~ Lion of HPC
is slower than that of CAP bec~-lse HPC is retained in methanol which evaporates slower than ~cetone. The.~fole, the CAP-~cetone system ~ives a ~ porous structure. The HPC deposits on the s~ ce of the primary membrane pores.
Mesityle~e was used as a pore-former in ~e membrane. Mesitylene is a non-solvent to the CAP, HPC and dextran. Mesitylene has a much higher boiling point than either acetone or methanol. Thus, it rem~in~ in the membrane for a longer time than acetone or methanol. This enables mesitylene to be a good former of secondary membrane pores.
A typical formulation for a membrane solution is as follows:
Cellulose Acetate Propionate 1.25% POLYMER 1 Klucel Hydroxypropyl Cellulose 1.25% POLYMER 2 Dextran MW 87,000 g/mol 0.25% POLYMER 3 ~ = ~ ==
2~6204~
Surfactant (Fluorad FC 1 70C, 3M Company Commercial Chemicals Division, St. Paul, Minnesota, USA) 0.25%
Acetone 43.5%
Methanol 43.5%
Mesitylene 1 0.0%
The resultant membrane when using a spraying dist~nce of 4.0 cm had an average pore size of 7 !lm, as determined by sc~nning electron mlcroscopy.
Apart from cellulose acetate propionate, there are many hydrophobic polymers with good solubility in organic solvents which can be used as the POLYMER 1 in the membrane form~ tion- These polymers include cellulose acetate, polyvinyl butyral, polystyrene, etc.
Alternatives to the hydroxypropyl cellulose, which can be used as the POLYMER 2 and have good solubility in organic solvents include polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl ~cet~te, etc.
There are ~ltç~ ~ve polymers apart from dextran, which can be used as POLYMER 3 in the membrane formulations. These polymers should have high molecular weights, good hydrophilicity and should be soluble in organic solvents. Some positively cllalged polymers with good hydrophilicity and with modest to good solubility in organic solvents can also be used. These alternatives to dextran include polylysine, polybrene, .ot~i~le, etc.
F~r~mple 3 The main advantage of plasma se~tion is a reduction in the red cell elrere.~ce on the sensor electrodes. This illle-r~rence is due to diffilsional limit~tion and some interfering reaction. Wi~ increasing haematocrit there is a reduction response at the sensor electrode at a constant analyte concentration. With an effective red cell exclusion membrane a reduced haematocrit response is expected.
wo 94/27140 21 6 2 04 5 16 PCT/GB94101011 Electrode test strips for glucose were made in accordance with EP-A
127958, using screen printing. The m~nl;~f~cturing process was much the same as that described in Exarnple 1 for the m~n~lf~cture of electrode test strips for cholesterol, except that the working electrode was prepared from commercially produced glucose oxidase and binder. These were reconstituted in BES buffer pH 7.4 for 2 hours prior to addition of ultrafine carbon and l,l'-dimethylferrocene ethanolamine as mediator.
Batches of the strips were sprayed at different distances with the formulation of Example 2 to form membranes of di~rellt pores sizes.
The following results for glucose sensors in accordance with EP-A
127958, with and without membranes, show the relative reduction in h~em~tocrit response, corrected for glucose sensitivity.
Spraying Membrane Relative E~em~tocrit Distance (cm) Pore Size (,um) Response (%) Uncoated 1 00 electrodes Membrane coated 3.5 10 45.4 electrodes Membrane coated 4.0 7 23.3 electrodes Membrane coated 5.5 2 33.1 electrodes In this experiment the 7 ~m pore size membrane gave the greatest reduction in relative h~m~tocrit sensitivity.
Example 4 The dip-coating technique was also used to produce membranes for test strips for glucose sensors in accordance with EP-A 127958. The construction of the resultant test strip is illustrated in Figure 5.
Nylon mesh was dipped into the polyrner solutions to allow the nylon mesh to be coated with the polymer solution. The coated nylon mesh was then removed from the polymer solution and allowed to dry. These 21620~
procedures gave a ullifol~ polymeric membrane on the nylon mesh. In fine-tuning the membrane morphology, rinsing and then washing of the dip-coated nylon mesh with water, to give more porous membrane morphology was carried out.
A typical polymer solution used for dip-coating the nylon mesh is givenbelow, and cont~ined CAP, ~'C, tetrahydrofuran (T~), cyclohexanone and dioctyl phth~1~te. In this solution, CAP, the major membrane material, formed the rigid skeleton of the membrane system. HPC
contributed to the formation of microporous structure and to the hydrophilicity of the membrane system. By altering the ratio of CAP and HPC in the polymer solution, it is possible to control the porosity of the membrane structure. THF is the major solvent used in the polymer solution. T~ plays an important role in inllur.in~ the L~ ;on of a microporous m~.mbrane structure. Under the e~c.;... ~l~1 conditions, it was found that the evaporation rate of the THF was high, and there was some difficulty in obt~inin~ membranes of w~irOllll thickness.
Cyclohexanone was used as a minor solvent for CAP and for HPC. By altering the ratio of the THF and cycloh~x~none, the solvent evaporation rate was controlled to a s~ti~f~ctory degree to achieve a membrane of accurate thiçkness. The porosity increæed with increasing amounts of cyclohe~none. Dioctyl phth~l~te was used to provide plasticity to the membrane s¢ucture. This was bec~llse a membrane con~i~tinE of CAP
and HPC can be brittle. Dioctyl phth~1~te wæ çhosen in this context bec~llce its physicochemical nature allows it to assist the diffusion of plasma through t~e membrane.
Nylon mesh was dipped for a few seconds into the polymer solutions.
The mesh was then rinsed with water at ambient temp~lule for 5 seconds to induce the precipitation of CAP and the extraction of part of the HPC
from the membrane assembly. The system was then dip-coated with a mixture of !% dextran, 1% surf~ct~nt and water at ambient ~empc~ re, and dried in air. In the dip-co~in~ technique used in this study, the water rinse was designed to induce the precipila~ion of CAP and to dissolve part of the HPC cont~ined in the cast polymer solution, to improve the efficiency of plasma transport. The water rinse helps the forrnation of the porous swcture in the membrane, to provide desired hydrophilicity. The WO 94/27140 21~ 6 2 0 ~ ~ 18 PCT/GB94/01011 coated nylon mesh was then fixed onto the electrode surface of both the cholesterol electrodes and the glucose electrodes.
Polymeric materials were investigated for their suitability as ingredients in a dip-coating formulation. A prefelled dip-coating membrane formulation was found to be as follows:
Polymer %
CAP 2 Polymer 1 E~'C 2 Polymer 2 THF 85 Solvent 1 Cyclohexanone 4 Solvent 2 Dioctyl phth~l~te 7 Additive The surface morphology of a typical dip-coated nylon mesh membrane was ~x~...;.,ed by sc~nning electron microscopy, showing porous structures with an average pore size of 4 ~lm.
Screen printed sensors for cholesterol were plc~alcd in accordance with EP-A 230786, with and without the dip-coated membrane.
On testing it was found that the cholesterol electrodes with membrane gave higher electrode cull~nls than the cholesterol electrodes without membrane, and higher values i-t integration.
From statistical analysis of the data, it was concluded that the me~llbla.le cholesterol electrodes have higher sensitivity to the cholesterol than do the ordinary cholesterol clc. lsodes. This is in-lic.~te-l by the higher slope of cholesterol calibration line for the membrane cholesterol electrodes (10.539) than that for the ordill~y cholesterol electrodes (5.412).
Tests for the h~P.~ ocrit effect were carried out on the ordi,l~y cholesterol electrodes and the cholesterol electrodes covered with dip-coated membranes in order to evaluate the ability of the membrane to separate erythrocytes from blood samples. The blood samples were as follows:
Sample 1: E~em~tQcrit level = 36%
æ~o4~
Cholesterol concentratiOn = 6.98 mM.
Sample 2: ~em~tocrit level = 44%
Cholesterol concentration = 6.98 mM.
Sample3: Haematocr~tlevel = 54%
- Cholesterol concentration = 6.98 mM.
The i-t transients were obtained and integrated over the period 27~0 seconds, in order to carry out haematocrit effect analysis. The average statistical pararneters for the tested batch associated with the haematocrit effect lines are given in the next table.
ElectrodeType Slope s Intercept ~i R
No Membrane -0;137 0.051 21.725 2.306 0.5982 Membrane -0.072 0.124 19.648 5.478 0.2510 From the table, it can be concluded there is a reduced h~em~tocrit effect using the dip-coated nylon meehes. There is a re-lnction of the absolute value ofthe slope ofthe h~P..,~tocrit effect lines from 0.137 (for t_e or~li,l~y cholesterol electrodes) to 0.0721 (for the mçmbrane-treated cholesterol electrodes).
Fx~mple 5 Dextran has limite~l solubility in many organic solvents. Another ~ploach to the incl~leion of dextran in the membrane assemblies is spray-c~etin~ of a two-layer, membrane assembly. The idea involves spray-c~etin~ a polymer solution co~ CAP and HPC as the first membrane layer followed by spray-c~etin~ a polymer solution co~ dextran on top of the first membrane layer. The construction of the resl-lt~nt test strip is illustrated in Figure 6.
The hydrophobic polymer and the hy~o~ ilic polyrners can be prepared for the c~tin~ of the first membrane layer. The erythrocyte aggregating agent material, dextran, can be dissolved in ethylene glycol to give the polymer solution for the casting as the second membrane layer. Polymer solutions either cont~ining both ~'C and dextran were l,re~aled. Since ethylene glycol has too low a volatility, a l~ixLule of ethanol and ethylene glycol was use~als ~e so~vent in preparation of the solution for the second membrane layer.
Membranes with different contents of dextran were prepared. These membranes consisted of two membranes layers each approximatelv 5 to 10 ~m in thickness. The first membrane layer contained 50% of CAP and 50% of HPC. The second membrane layer cnn~i~ted of dextran and HPC.
The composition of dextran in the second layer was varied to allow assessment of the function of dextran in the separation of erythrocvtes.
The fo~ tions of the polymer solution for c~stin~ of the second membrane layer are given in the next table. These polymer solutions contain 90% of ethylene glycol.
Solutions Compositions (%) Dextran HPC
0.0 10.0 2 2.5 7.5 3 5.0 5.0 4 7.5 2.5 0.0 The cholesterol electrodes, coated with the CAP/HPC (50%:50%, first layer) and dextran/~C (secon~ layer), were tested for their ef~iciency in se~ g e~rocytes and in tran~o~ g cholesterol.
Whole hllm~n blood samples were used, as follows:
Sample 1: ~tn~tocrit level = 32%
Sample 2: E~m~tocrit level = 34%, Sample 3: H~tn~tocrit level = 48%.
The i-t transients were integrated over the period of 15-30 seconds, and from ~e SD values, it can be concluded that the i-t transients obtained have s~ti~f~ctory overall reproducibility.
The h~em~tocrit effect lines were plotted, giving the following data.
2~ q5 WO 94/27140 21 ` PCT/GB94/01011 Dextran (%) Slope ~s Intercept ~i R
- 0.0 -0.427 0.045 30.055 1.886 0.984 2.5 -0.156 0.048 20.028 1.971 0.916 5.0 -0.003 0.141 17.350 5.751 0.010 7.5 -0.044 0.120 18.987 4.899 0.180 10.0 -0.052 0.025 14.360 1.040 0.822 These results shown the ability of dextran to facilitate the exclusion of eIythrocytes, as demonstrated by the decrease in absolute value of the slopes from 0.427 to 0.003.
Claims (16)
1. An erythrocyte exclusion membrane for a sensor, said membrane comprising a porous polymeric matrix and a water-soluble erythrocyte aggregating agent.
2. The membrane of Claim 1, wherein said porous matrix comprises a water-insoluble hydrophobic polymer and a water-soluble hydrophilic polymer.
3. The membrane of Claim 1, wherein said porous matrix comprises pores of pore diameters in the range 1 to 15 µm.
4. The membrane of claim 1, comprising a single layer.
5. The membrane of Claim 1, comprising first and second layers, said first layer comprising said porous matrix and said second layer including said erythrocyte aggregating agent.
6. The membrane of Claim 1, further including a porous support.
7. The membrane of Claim 1, wherein said hydrophobic polymer is selected from the group consisting of cellulose acetate propionate, cellulose acetate, polyvinyl butyral and polystyrene.
8. The membrane of Claim 1, wherein said hydrophilic polymer is selected from the group consisting of hydroxypropyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol and polyvinyl acetate.
9. The membrane of Claim 1, wherein said erythrocyte aggregating agent is a mobile erythrocyte aggregating agent selected from the group consisting of dextran, polylysine salts, polybrene, and protamine.
10. The membrane of Claim 2, wherein said erythrocyte aggregating agent is more water-soluble than said water-soluble hydrophilic polymer.
11. The membrane of Claim 1, wherein the pores of said porous polymeric matrix have pore diameters in the range 1 to 15 µm.
12. The membrane of Claim 11, wherein the pores of said porous polymeric matrix have pore diameters in the range 3 to 15 µm.
13. A test strip for an electrochemical sensor for contact with whole blood in order to effect an electrochemical measurement, said test strip having an exclusion layer in the form of a porous polymeric membrane with a mobile erythrocyte aggregating agent.
14. The test strip of Claim 13, which is an amperometric test strip having electrode areas overlain by said exclusion layer.
15. The test strip of Claim 14, wherein said exclusion layer has a thickness in the range 20 to 50 µm.
16. A method of manufacturing a test strip for an electrochemical sensor, said test strip having an erythrocyte exclusion membrane of polymeric material,, said method comprising the steps of providing a sprayable solution of said polymeric material, and spraying said sprayable solution to form said membrane in situ on said test strip.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939309797A GB9309797D0 (en) | 1993-05-12 | 1993-05-12 | Electrochemical sensors |
GB9309797.0 | 1993-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2162045A1 true CA2162045A1 (en) | 1994-11-24 |
Family
ID=10735356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002162045A Abandoned CA2162045A1 (en) | 1993-05-12 | 1994-05-11 | Electrochemical sensors |
Country Status (7)
Country | Link |
---|---|
US (1) | US5658444A (en) |
EP (1) | EP0698206B1 (en) |
AU (1) | AU6685694A (en) |
CA (1) | CA2162045A1 (en) |
DE (1) | DE69411732T2 (en) |
GB (1) | GB9309797D0 (en) |
WO (1) | WO1994027140A1 (en) |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5708247A (en) * | 1996-02-14 | 1998-01-13 | Selfcare, Inc. | Disposable glucose test strips, and methods and compositions for making same |
US6241862B1 (en) | 1996-02-14 | 2001-06-05 | Inverness Medical Technology, Inc. | Disposable test strips with integrated reagent/blood separation layer |
US7112265B1 (en) * | 1996-02-14 | 2006-09-26 | Lifescan Scotland Limited | Disposable test strips with integrated reagent/blood separation layer |
DE19605582A1 (en) * | 1996-02-15 | 1997-08-21 | Bayer Ag | Graphite nonwovens as functional layers in diagnostic test kits |
DE19605583A1 (en) | 1996-02-15 | 1997-08-21 | Bayer Ag | Electrochemical sensors with improved selectivity and increased sensitivity |
US5859537A (en) * | 1996-10-03 | 1999-01-12 | Dacco Sci, Inc. | Electrochemical sensors for evaluating corrosion and adhesion on painted metal structures |
JP3460183B2 (en) * | 1996-12-24 | 2003-10-27 | 松下電器産業株式会社 | Biosensor |
DE69809391T2 (en) | 1997-02-06 | 2003-07-10 | Therasense Inc | SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION |
JP3297630B2 (en) | 1997-07-28 | 2002-07-02 | 松下電器産業株式会社 | Biosensor |
US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6752964B1 (en) * | 1998-06-23 | 2004-06-22 | California Institute Of Technology | Polymer/plasticizer based sensors |
US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6565738B1 (en) * | 1999-01-28 | 2003-05-20 | Abbott Laboratories | Diagnostic test for the measurement of analyte in abiological fluid |
JP2002537031A (en) | 1999-02-18 | 2002-11-05 | バイオバルブ テクノロジーズ インコーポレイテッド | Electroactive pores |
DE19912120A1 (en) * | 1999-03-18 | 2000-09-28 | Fraunhofer Ges Forschung | Procedure for the isolation of erythrocytes |
US6696240B1 (en) | 1999-10-26 | 2004-02-24 | Micronix, Inc. | Capillary test strip to separate particulates |
US6319719B1 (en) | 1999-10-28 | 2001-11-20 | Roche Diagnostics Corporation | Capillary hematocrit separation structure and method |
WO2001038873A2 (en) * | 1999-11-24 | 2001-05-31 | Biotronic Technologies, Inc. | Devices and methods for detecting analytes using electrosensor having capture reagent |
US6406672B1 (en) | 2000-01-28 | 2002-06-18 | Roche Diagnostics | Plasma retention structure providing internal flow |
US6451264B1 (en) | 2000-01-28 | 2002-09-17 | Roche Diagnostics Corporation | Fluid flow control in curved capillary channels |
WO2001090733A1 (en) * | 2000-05-23 | 2001-11-29 | Radiometer Medical A/S | A sensor membrane, a method for the preparation thereof, a sensor and a layered membrane structure for such sensor |
WO2002010734A1 (en) * | 2000-07-31 | 2002-02-07 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
WO2002010735A1 (en) * | 2000-07-31 | 2002-02-07 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
DE10052066A1 (en) * | 2000-10-19 | 2002-05-29 | Inverness Medical Ltd | Screen printable paste for the production of a porous polymer membrane for a biosensor |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7682318B2 (en) | 2001-06-12 | 2010-03-23 | Pelikan Technologies, Inc. | Blood sampling apparatus and method |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US7749174B2 (en) | 2001-06-12 | 2010-07-06 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge |
EP1404234B1 (en) | 2001-06-12 | 2011-02-09 | Pelikan Technologies Inc. | Apparatus for improving success rate of blood yield from a fingerstick |
DE60234598D1 (en) | 2001-06-12 | 2010-01-14 | Pelikan Technologies Inc | SELF-OPTIMIZING LANZET DEVICE WITH ADAPTANT FOR TEMPORAL FLUCTUATIONS OF SKIN PROPERTIES |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
ATE485766T1 (en) | 2001-06-12 | 2010-11-15 | Pelikan Technologies Inc | ELECTRICAL ACTUATING ELEMENT FOR A LANCET |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US6755949B1 (en) | 2001-10-09 | 2004-06-29 | Roche Diagnostics Corporation | Biosensor |
JPWO2003042679A1 (en) * | 2001-11-14 | 2005-03-10 | 松下電器産業株式会社 | Biosensor |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7892185B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
CZ297082B6 (en) * | 2002-06-03 | 2006-09-13 | Ing. Ilja Krejcí-Engineering | Three-dimensional components prepared by thick film technology and method of producing thereof |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US7767068B2 (en) | 2002-12-02 | 2010-08-03 | Epocal Inc. | Heterogeneous membrane electrodes |
US7842234B2 (en) * | 2002-12-02 | 2010-11-30 | Epocal Inc. | Diagnostic devices incorporating fluidics and methods of manufacture |
US7094330B2 (en) * | 2002-12-02 | 2006-08-22 | Epocal Inc. | Heterogeneous membrane electrodes |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US8771183B2 (en) | 2004-02-17 | 2014-07-08 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
EP1628567B1 (en) | 2003-05-30 | 2010-08-04 | Pelikan Technologies Inc. | Method and apparatus for fluid injection |
DK1633235T3 (en) | 2003-06-06 | 2014-08-18 | Sanofi Aventis Deutschland | Apparatus for sampling body fluid and detecting analyte |
KR100554649B1 (en) * | 2003-06-09 | 2006-02-24 | 주식회사 아이센스 | Electrochemical biosensor |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
EP1680014A4 (en) | 2003-10-14 | 2009-01-21 | Pelikan Technologies Inc | Method and apparatus for a variable user interface |
US8007656B2 (en) * | 2003-10-24 | 2011-08-30 | Bayer Healthcare Llc | Enzymatic electrochemical biosensor |
USD914881S1 (en) | 2003-11-05 | 2021-03-30 | Abbott Diabetes Care Inc. | Analyte sensor electronic mount |
EP1706026B1 (en) | 2003-12-31 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Method and apparatus for improving fluidic flow and sample capture |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US7384791B2 (en) * | 2004-01-21 | 2008-06-10 | Hewlett-Packard Development Company, L.P. | Method of analyzing blood |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
EP1765194A4 (en) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Method and apparatus for a fluid sampling device |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US8425858B2 (en) * | 2005-10-14 | 2013-04-23 | Morpho Detection, Inc. | Detection apparatus and associated method |
US20070086916A1 (en) * | 2005-10-14 | 2007-04-19 | General Electric Company | Faceted structure, article, sensor device, and method |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
ITBO20060397A1 (en) * | 2006-05-24 | 2007-11-25 | Consiglio Nazionale Ricerche | MACHINE FOR AUTOMATED MATERIAL DEPOSITION BY MEANS OF AN AIRBRUSH |
WO2008079731A1 (en) * | 2006-12-22 | 2008-07-03 | Home Diagnostics, Inc. | Gel formation to reduce hematocrit sensitivity in electrochemical test |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
CN102016596B (en) * | 2008-03-27 | 2014-09-17 | 哈佛学院院长等 | Paper-based microfluidic systems |
WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
CN102227636A (en) * | 2008-09-30 | 2011-10-26 | 梅纳伊医疗科技有限公司 | Sample measurement system |
US20110210014A1 (en) * | 2008-11-03 | 2011-09-01 | Garosshen Thomas J | Corrosion sensor system |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US20100213057A1 (en) | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
WO2011026148A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
WO2011041469A1 (en) | 2009-09-29 | 2011-04-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
GB201005357D0 (en) | 2010-03-30 | 2010-05-12 | Menai Medical Technologies Ltd | Sampling plate |
GB201005359D0 (en) | 2010-03-30 | 2010-05-12 | Menai Medical Technologies Ltd | Sampling plate |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
EP2583090B1 (en) | 2010-06-15 | 2016-04-06 | 3M Innovative Properties Company | Variable capacitance sensors and methods of making the same |
US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
KR101367262B1 (en) | 2011-11-11 | 2014-02-26 | 주식회사 아이센스 | Blood Glucose Sensor and sensing error detecting method using thereof |
GB201207869D0 (en) * | 2012-05-04 | 2012-06-20 | Accunostics Ltd | Pulsed signal testing of biological fluid |
KR101466222B1 (en) | 2012-06-01 | 2014-12-01 | 주식회사 아이센스 | Electrochemical biosensor with improved accuracy |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
GB201302292D0 (en) * | 2013-02-08 | 2013-03-27 | Whatman Gmbh | Medical diagnostic test systems,and a matrix therefor |
JP7062272B2 (en) * | 2018-03-06 | 2022-05-06 | 公立大学法人北九州市立大学 | Sensor chip and its manufacturing method, analyzer, and analysis method |
EP4317957A1 (en) * | 2022-08-05 | 2024-02-07 | Fundació Eurecat | Additive manufacturing of sensors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3662046A (en) * | 1970-06-03 | 1972-05-09 | Us Interior | Method of making reverse osmosis membranes for desalination of water |
DE3278334D1 (en) * | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
US5509410A (en) * | 1983-06-06 | 1996-04-23 | Medisense, Inc. | Strip electrode including screen printing of a single layer |
CA1226036A (en) * | 1983-05-05 | 1987-08-25 | Irving J. Higgins | Analytical equipment and sensor electrodes therefor |
DE3323973A1 (en) * | 1983-07-02 | 1985-01-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | ERYTHROCYTE RETENTION SUBSTRATES |
CA1249025A (en) * | 1984-10-12 | 1989-01-17 | Anthony E.G. Cass | Chemical sensor for n-acetyl primary aromatic amines |
GB8531755D0 (en) * | 1985-12-24 | 1986-02-05 | Genetics Int Inc | Assay for cholestrol & derivatives |
GB8709882D0 (en) * | 1987-04-27 | 1987-06-03 | Genetics Int Inc | Membrane configurations |
JPH02140147A (en) * | 1988-01-19 | 1990-05-29 | Syntex Usa Inc | Method and apparatus for separating blood plasma from red corpuscle |
US5306623A (en) * | 1989-08-28 | 1994-04-26 | Lifescan, Inc. | Visual blood glucose concentration test strip |
AU640162B2 (en) * | 1989-08-28 | 1993-08-19 | Lifescan, Inc. | Blood separation and analyte detection techniques |
DE4015589A1 (en) * | 1990-05-15 | 1991-11-21 | Boehringer Mannheim Gmbh | DEVICE AND THE USE THEREOF FOR SEPARATING PLASMA FROM WHOLE BLOOD |
US5166051A (en) * | 1990-08-08 | 1992-11-24 | Genesis Labs, Inc. | Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes |
-
1993
- 1993-05-12 GB GB939309797A patent/GB9309797D0/en active Pending
-
1994
- 1994-05-11 EP EP94914508A patent/EP0698206B1/en not_active Expired - Lifetime
- 1994-05-11 US US08/545,805 patent/US5658444A/en not_active Expired - Fee Related
- 1994-05-11 AU AU66856/94A patent/AU6685694A/en not_active Abandoned
- 1994-05-11 CA CA002162045A patent/CA2162045A1/en not_active Abandoned
- 1994-05-11 DE DE69411732T patent/DE69411732T2/en not_active Expired - Fee Related
- 1994-05-11 WO PCT/GB1994/001011 patent/WO1994027140A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO1994027140A1 (en) | 1994-11-24 |
DE69411732T2 (en) | 1999-02-25 |
EP0698206B1 (en) | 1998-07-15 |
US5658444A (en) | 1997-08-19 |
GB9309797D0 (en) | 1993-06-23 |
EP0698206A1 (en) | 1996-02-28 |
AU6685694A (en) | 1994-12-12 |
DE69411732D1 (en) | 1998-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2162045A1 (en) | Electrochemical sensors | |
US4886740A (en) | Enzyme-electrode sensor with organosilane treated membrane | |
US4240889A (en) | Enzyme electrode provided with immobilized enzyme membrane | |
JP3220486B2 (en) | Visible test strip for blood glucose concentration | |
JP4763777B2 (en) | Enzyme sensor comprising a cover membrane layer coated with a hydrophilic polymer | |
EP0359831B1 (en) | Biosensor and process for its production | |
US6436255B2 (en) | Biosensor | |
US5229282A (en) | Preparation of biosensor having a layer containing an enzyme, electron acceptor and hydrophilic polymer on an electrode system | |
CN101184851B (en) | Enzyme sensor including a water-containing spacer layer | |
FI91331C (en) | Sensor | |
JP3406089B2 (en) | Dry analytical element containing amphoteric electrolyte | |
US20030125403A1 (en) | Paste, which can undergo screen printing, for producing a porous polymer membrane for a biosensor | |
CZ227697A3 (en) | Diagnostic test carrier and the use thereof | |
EP0442969A1 (en) | Wholly microfabricated biosensors and process for the manufacture and use thereof | |
CN108291889B (en) | Outer layer for enzyme sensor | |
DE2638193C3 (en) | Laminated membrane for use in an enzyme electrode and method of making such a membrane | |
EP0859954B1 (en) | Biosensors comprising a membrane | |
JP3285879B2 (en) | Sensor and modified membrane for this sensor | |
EP0546032B1 (en) | Immobilization of organic macromolecules or biopolymers in a polymer membrane | |
CN112014448A (en) | Biosensor, method for manufacturing the same, and polymer film layer for biosensor | |
JP4493535B2 (en) | Test paper | |
WO1988009824A1 (en) | Improvements in diagnostic test strips | |
DE102004003793A1 (en) | Reagent-carrying layer for electrochemical biosensors, e.g. for detecting substances such as creatinine in body fluids, comprises a layer of reagent-containing polymer and a thin, water-resistant, permeable surface layer | |
US8202490B2 (en) | Membranes and methods for coating membranes | |
US7816112B2 (en) | Castable diffusion membrane for enzyme-based sensor application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |